Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.43), $0.04 better than the analyst estimate of ($0.47).

As of December 31, 2015, cash, cash equivalents and marketable securities totaled $105.1 million. Cash used in operating activities was $8.6 million in the fourth quarter of 2015 and $33.7 million for the year ended December 31, 2015. There was $15.6 million in outstanding debt as of December 31, 2015 and no principal payments are due until January 2017. The Company expects that cash, cash equivalents and marketable securities will be sufficient to fund operating expenses, debt service obligations and capital expenditures through the third quarter of 2017.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.